Risk and timing of isotretinoin-related laboratory disturbances: a population-based study.

Isotretinoin is associated with a clinically marginal increased risk of severe hypertriglyceridemia and hypertransaminasemia. Routine blood testing should be performed 1-3 months after commencing therapy.